Viewing Study NCT05982834


Ignite Creation Date: 2025-12-25 @ 2:34 AM
Ignite Modification Date: 2026-03-02 @ 4:55 PM
Study NCT ID: NCT05982834
Status: RECRUITING
Last Update Posted: 2023-08-09
First Post: 2023-05-19
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Disitamab Vedotin, Fruquintinib and Tislelizumab in Second-line Treatment for HER2-positive MGC
Sponsor: Fudan University
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module